| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.20.2.556 |
| P698 | PubMed publication ID | 10669656 |
| P2093 | author name string | P Libby | |
| T Bourcier | |||
| P433 | issue | 2 | |
| P921 | main subject | plasminogen | Q107129060 |
| P304 | page(s) | 556-562 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells | |
| P478 | volume | 20 |
| Q35111806 | 3-Hydroxy-3-methylglutaryl–Coenzyme A Reductase Inhibitors in the Treatment of Central Nervous System Diseases |
| Q35556348 | Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins |
| Q90169905 | Atorvastatin Reduces In Vivo Fibrin Deposition and Macrophage Accumulation, and Improves Primary Patency Duration and Maturation of Murine Arteriovenous Fistula |
| Q35196188 | Benefits and risks of simvastatin in patients with familial hypercholesterolaemia |
| Q34875099 | Beyond lipid lowering: the role of statins in vascular protection |
| Q37507632 | Can we use statins to prevent stroke in Fabry disease? |
| Q37013011 | Circulating Thrombotic Risk Factors in Young Patients with Coronary Artery Disease Who Are on Statins and Anti-platelet Drugs |
| Q36998040 | Clinical review: Statins and trauma--a systematic review |
| Q36985325 | Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. |
| Q37170931 | Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event |
| Q44545087 | Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. |
| Q35952218 | Do statins offer therapeutic potential in inflammatory arthritis? |
| Q24804153 | Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? |
| Q36561336 | Effect and Safety of Rosuvastatin in Acute Ischemic Stroke |
| Q44318791 | Effect of atorvastatin and clopidogrel on cellular immune function. |
| Q46198283 | Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia |
| Q64082914 | Effect of statins on the association between high temperature and all-cause mortality in a socioeconomically disadvantaged population: a cohort study |
| Q34106488 | Effects of HMG-CoA reductase inhibitor on hemostasis |
| Q35200997 | Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes |
| Q42151480 | Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure |
| Q34990662 | Effects of lipids on thrombotic mechanisms in atherosclerosis |
| Q44378566 | Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease |
| Q35050141 | Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. |
| Q36242351 | Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol |
| Q37351215 | Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation |
| Q44597999 | HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells |
| Q28344912 | HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins |
| Q38030483 | HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis |
| Q35169109 | Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells |
| Q40616218 | Increased Expression of Plasminogen Activator Inhibitor-1 by Mediators of the Acute Phase Response: a Potential Progenitor of Vasculopathy in Hypertensives |
| Q44026877 | Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes |
| Q36014039 | Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials |
| Q37341566 | Long-term benefits after treatment of traumatic brain injury with simvastatin in rats |
| Q35077211 | Mechanisms of plaque stabilization with statins |
| Q34466935 | Nonlipid-lowering effects of statins |
| Q37118404 | Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. |
| Q37451760 | Physiologic inhibitors of coagulation in patients on chronic hemodialysis |
| Q42446576 | Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells |
| Q34384926 | Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease |
| Q34376916 | Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. |
| Q39069187 | Pleiotropic Effects of Statins on the Cardiovascular System |
| Q37027838 | Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. |
| Q24647863 | Pleiotropic effects of statins |
| Q36025981 | Pleiotropic effects of statins: moving beyond cholesterol control |
| Q37403235 | Pleiotropic vasoprotective effects of statins: the chicken or the egg? |
| Q44123157 | Policosanol safely down-regulates HMG-CoA reductase - potential as a component of the Esselstyn regimen |
| Q35075417 | Preexisting statin use is associated with greater reperfusion in hyperacute ischemic stroke |
| Q42955705 | Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study |
| Q42552752 | Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia |
| Q28196500 | Prothrombotic and antithrombotic pathways in acute coronary syndromes |
| Q44413736 | Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway |
| Q36884340 | Serpins in thrombosis, hemostasis and fibrinolysis |
| Q36385133 | Should all diabetic patients receive statins? |
| Q40676331 | Simvastatin stimulates VEGF release via p44/p42 MAP kinase in vascular smooth muscle cells |
| Q37146694 | Spectrum of pleiotropic effects of statins in heart failure |
| Q34986368 | Stabilization of atherosclerotic plaques: new mechanisms and clinical targets |
| Q49292081 | Statin Therapy Negatively Impacts Skeletal Muscle Regeneration and Cutaneous Wound Repair in Type 1 Diabetic Mice |
| Q36142655 | Statin mediated protection of the ischemic myocardium |
| Q36763374 | Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke |
| Q35936804 | Statin therapy for cardiac hypertrophy and heart failure |
| Q37098888 | Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts |
| Q36153662 | Statin withdrawal beyond acute phase affected outcome of thrombolytic stroke patients: an observational retrospective study |
| Q28366335 | Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I |
| Q33960556 | Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy |
| Q33921904 | Statins and delirium during critical illness: a multicenter, prospective cohort study |
| Q36797719 | Statins and sepsis: multiple modifications at multiple levels. |
| Q81623503 | Statins and stroke |
| Q36110624 | Statins and the myocardium |
| Q42991831 | Statins as a novel therapeutic strategy in acute lung injury |
| Q36768488 | Statins as first-line therapy for acute coronary syndrome? |
| Q27317154 | Statins improve the resolution of established murine venous thrombosis: reductions in thrombus burden and vein wall scarring |
| Q35604889 | Statins in coronary bypass surgery: rationale and clinical use. |
| Q37276056 | Statins in endothelial signaling and activation |
| Q36070423 | Statins in hypertensive patients: potential explanations for the ASCOT-LLA study results |
| Q37276466 | Statins in the first-line therapy of acute coronary syndrome - similar to aspirin? |
| Q37279038 | Statins inhibit Rho kinase activity in patients with atherosclerosis |
| Q36428724 | Statins: panacea for sepsis? |
| Q22252405 | The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes |
| Q36566297 | The association of prior statin use in septic shock treated with early goal directed therapy. |
| Q36876210 | The effect of statin therapy on the incidence of infections: a retrospective cohort analysis. |
| Q36429347 | The effects of HMG-CoA reductase inhibitors on endothelial function |
| Q38605504 | The immune system in atherosclerosis and in acute myocardial infarction |
| Q35744631 | The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach |
| Q42437067 | Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin |
| Q36382348 | Toll-like receptors and human disease: lessons from single nucleotide polymorphisms |
| Q44204907 | Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components |
| Q45204273 | Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. |
| Q36894180 | Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. |
Search more.